{"count": 2, "results": [{"_id": "17563269", "pmid": 17563269, "title": "Metformin/rosiglitazone combination pill (Avandamet) for the treatment of patients with Type 2 diabetes.", "journal": "Expert Opin Pharmacother", "authors": ["Smiley D", "Umpierrez G"], "date": "2007-06-01T00:00:00Z", "doi": "10.1517/14656566.8.9.1353", "meta_date_publication": "2007 Jun", "meta_volume": "8", "meta_issue": "9", "meta_pages": "1353-64", "score": 50061.996, "text_hl": "As @DISEASE_Insulin_Resistance @DISEASE_MESH:D007333 @@@insulin resistance@@@ is a pathophysiologic cornerstone of @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes@@@ and @<m>DISEASE_Cardiovascular_Diseases</m> @DISEASE_MESH:D002318 @@@cardiovascular disease@@@, the use of @<m>CHEMICAL_rosiglitazone_metformin_combination</m> @CHEMICAL_MESH:C471074 @@@Avandamet@@@ represents an optimal approach to the treatment of @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes@@@. ", "citations": {"NLM": "Smiley D, Umpierrez G. Metformin/rosiglitazone combination pill (Avandamet) for the treatment of patients with Type 2 diabetes. Expert Opin Pharmacother. 2007 Jun;8(9):1353-64. PMID: 17563269", "BibTeX": "@article{17563269, title={Metformin/rosiglitazone combination pill (Avandamet) for the treatment of patients with Type 2 diabetes.}, author={Smiley D and Umpierrez G}, journal={Expert Opin Pharmacother}, volume={8}, number={9}, pages={1353-64}}"}}, {"_id": "21595121", "pmid": 21595121, "title": "Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations: Final Original Report", "journal": "", "authors": ["Jonas D", "Van Scoyoc E", "Gerrald K", "Wines R", "Amick H", "Triplette M", "Runge T"], "date": "2011-02-01T00:00:00Z", "meta_date_publication": "2011 Feb", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50022.477, "text_hl": "Therapy with @<m>CHEMICAL_rosiglitazone_metformin_combination</m> @CHEMICAL_MESH:C471074 @@@Avandamet@@@,<sup> </sup> Avandaryl,<sup> </sup> Actoplus Met, or dual therapy with @CHEMICAL_Metformin @CHEMICAL_MESH:D008687 @@@metformin@@@ and @CHEMICAL_Sitagliptin_Phosphate @CHEMICAL_MESH:D000068900 @@@sitagliptin@@@ produced statistically significantly greater reductions in HbA1c compared to monotherapy with any of their respective components. ", "citations": {"NLM": "Jonas D, Van Scoyoc E, Gerrald K, Wines R, Amick H, Triplette M, Runge T. Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations: Final Original Report . 2011 Feb;():. PMID: 21595121", "BibTeX": "@article{21595121, title={Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations: Final Original Report}, author={Jonas D and Van Scoyoc E and Gerrald K and Wines R and Amick H and Triplette M and Runge T}}"}}]}